* Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show
no
change in quarterly revenue when it reports results on August
10.
*
* Refinitiv's mean analyst estimate for Aethlon Medical Inc
is
for a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Aethlon
Medical
Inc is $6.5, above its last closing price of $0.34.
This summary was machine generated August 5 at 02:09 GMT. All
figures in US dollars unless otherwise stated